Alpine Immune Sc Stock Price, News & Analysis

Alpine Immune Sciences (NASDAQ: ALPN) reported Q3 2022 financial results, highlighting a cash position of $277.1 million, sufficient to support operations through 2025. The company successfully raised $113 million to accelerate the development of ALPN-303, showing promising results in clinical trials for autoimmune diseases, including IgA nephropathy. A phase 2 study in systemic lupus erythematosus is planned, along with basket studies in related conditions. However, collaboration revenue slightly declined to $8.4 million, and the company reported a net loss of $13.3 million.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced it will release its third quarter 2022 financial results on November 14, 2022, after market close. A conference call and live webcast will take place at 4:30 p.m. ET. The webcast will be accessible via their investor relations website, with a replay available for 90 days post-event. Alpine is focused on developing innovative immunotherapy treatments for autoimmune and inflammatory diseases, backed by strong research collaboration and a diverse pipeline of candidates.

Alpine Immune Sciences presented new data on ALPN-303 at the American Society of Nephrology Kidney Week 2022, showcasing its potential in treating IgA nephropathy (IgAN). The phase 1 study (RUBY-1) demonstrated that ALPN-303 is well tolerated in doses up to 960 mg and shows dose-dependent effects, reducing serum galactose-deficient IgA1 (Gd-IgA1) by up to 60%. These findings support plans for future clinical trials focusing on glomerulonephritis. The company emphasizes ALPN-303's best-in-class profile and its promising role in various autoimmune conditions.

Alpine Immune Sciences (NASDAQ: ALPN) announced a poster presentation at the American Society of Hematology meeting happening from December 10-13, 2022. The presentation will discuss the phase 1 study (RUBY-1) of ALPN-303, a dual BAFF/APRIL antagonist for treating autoimmune cytopenias. The study aims to assess the drug's safety, tolerability, and pharmacokinetics in healthy volunteers, with initial data supporting a dosing regimen of once every four weeks. The poster will be displayed on December 12, 2022, at 6:00 PM EST.

Alpine Immune Sciences (NASDAQ: ALPN) announces poster presentations for the phase 1 study of ALPN-303 at prestigious conferences. The American Society of Nephrology's Kidney Week 2022 and the American College of Rheumatology Convergence 2022 will showcase findings on the safety and pharmacokinetics of ALPN-303, a dual BAFF/APRIL antagonist targeting autoimmune diseases. Initial results show it is well tolerated with dose-dependent effects, supporting a once-every-four-week dosage regimen for future investigations.

Alpine Immune Sciences (NASDAQ: ALPN) has announced the voluntary termination of enrollment in its clinical studies for davoceticept (ALPN-202) due to patient safety concerns following two deaths in the NEON studies attributed to cardiogenic shock. The decision prioritizes the safety of participants and allows the company to redirect focus towards advancing ALPN-303, a promising dual BAFF/APRIL B cell cytokine inhibitor for autoimmune diseases, and acazicolcept (ALPN-101) for systemic lupus erythematosus. The company plans to conduct a phase 2 study for ALPN-303 and further evaluations in various autoimmune conditions.

Alpine Immune Sciences announced a public offering of 13,606,000 shares of common stock at $7.35 per share. Expected gross proceeds are approximately $100 million. The offering is conducted under an existing shelf registration statement. An additional 2,040,900 shares may be purchased by underwriters within 30 days. The offering aims to close on or about September 23, 2022. Morgan Stanley, SVB Securities, and Cowen are managing the offering. This press release includes forward-looking statements regarding market conditions and the offering's anticipated closure.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) has launched a public offering of $100 million in common stock, which includes pre-funded warrants for select investors. The underwriters may purchase an additional $15 million of shares within 30 days. The offering is subject to market conditions, with no guarantee of completion or specific terms. This follows their earlier filed shelf registration statement with the SEC. Morgan Stanley, SVB Securities, and Cowen are managing the offering.

Alpine Immune Sciences (NASDAQ: ALPN) reported significant clinical updates on its drug candidates ALPN-303 and Davoceticept (ALPN-202). ALPN-303 showed well-tolerated results in Phase 1 trials, targeting systemic lupus erythematosus (SLE) and other autoimmune diseases, with a Phase 2 study planned. Davoceticept demonstrated encouraging outcomes in renal cell carcinoma, particularly in combination with pembrolizumab. Management announced a webcast to discuss these developments, indicating a focused approach to advancing their clinical pipeline.